<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97603">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02108457</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 28813</org_study_id>
    <nct_id>NCT02108457</nct_id>
  </id_info>
  <brief_title>[18F] Flourothymidine (FLT) PET/CT Imaging for Gynecologic Cancers</brief_title>
  <official_title>[18F] Flourothymidine (FLT) PET/CT Imaging for Gynecologic Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of specific bone marrow maps developed
      with18F-FLT PET/CT imaging on the ability to spare proliferating bone marrow using proton
      beam radiotherapy compared to IMRT. Participants will be 18 years of age or old with a
      history of gynecologic cancer. Subjects will undergo 3 FLT-PET scans (one before treatment,
      one during the course of RT, and one 2-5 weeks after initiation of RT). Scans will take
      place in the Department of Radiation Oncology.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>up to 5 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Gynecologic Cancer</condition>
  <arm_group>
    <arm_group_label>Proton subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IMRT subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>[18F]Fluorothymidine (FLT) PET/CT Imaging</intervention_name>
    <arm_group_label>Proton subjects</arm_group_label>
    <arm_group_label>IMRT subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants will be 18 years of age or older

          -  History of gynecologic cancer.

          -  Recommended to undergo IMRT or PBT of the pelvis with concurrent chemotherapy

          -  Female participants of child-bearing potential must have a negative urine or serum
             pregnancy test at the time of the screening visit.

          -  Participants must be informed of the investigational nature of this study and provide
             written informed consent in accordance with institutional and federal guidelines
             prior to study specific procedures.

          -  Participants must be willing and able to comply with scheduled visits and imaging
             procedures in the opinion of the investigator or treating physician.

        Exclusion Criteria

          -  Females who are pregnant or breast feeding at the time of screening will not be
             eligible for this study.

          -  Inability to tolerate imaging procedures in the opinion of the investigator or
             treating physician

          -  Serious or unstable medical or psychological conditions that, in the opinion of the
             investigator would compromise the subjects safety or successful participation in the
             study.

          -  Unwilling or unable to provide informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lilie Lin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lilie Lin, MD</last_name>
    <phone>855-216-0098</phone>
    <email>PennCancerTrials@emergingmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lilie Lin, MD</last_name>
      <phone>855-216-0098</phone>
      <email>PennCancerTrials@emergingmed.com</email>
    </contact>
    <investigator>
      <last_name>Lilie Lin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 8, 2014</lastchanged_date>
  <firstreceived_date>April 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>concurrent chemotherapy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
